Tetrazole derivatives
US-2024382468-A2 · Nov 21, 2024 · US
Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
US2016115157A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016115157-A1 |
| Application number | US-201514972827-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 17, 2015 |
| Priority date | May 27, 2011 |
| Publication date | Apr 28, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound represented by the structure: wherein R 1 is a protecting group selected from the group consisting of acetyl, benzoyl, tert-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethyloxycarbonyl (FMOC), benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, and p-methoxyphenyl; and LG 1 is halo. 2 . The compound of claim 1 , wherein LG 1 is bromide. 3 . The compound of claim 1 , wherein LG 1 is iodide. 4 . The compound of claim 1 , having the structure: 5 . A compound represented by the structure: wherein R 1 is a protecting group selected from the group consisting of acetyl, benzoyl, tert-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethyloxycarbonyl (FMOC), benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, and p-methoxyphenyl; and LG 1 is halo. 6 . The compound of claim 5 , wherein LG 1 is bromide. 7 . The compound of claim 5 , wherein LG 1 is iodide. 8 . The compound of claim 5 , having the structure: 9 . A compound represented by the structure: wherein R 1 is a protecting group selected from the group consisting of acetyl, benzoyl, tert-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethyloxycarbonyl (FMOC), benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, and p-methoxyphenyl; and LG 2 is a 4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl group. 10 . The compound of claim 9 , having the structure: 11 . A compound represented by the structure: wherein R 1 is hydrogen or a protecting group selected from the group consisting of acetyl, benzoyl, tert-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethyloxycarbonyl (FMOC), benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, and p-methoxyphenyl. 12 . The compound of claim 11 , having the structure: 13 . The compound of claim 11 , having the structure:
Assignees
Inventors
Classifications
Spiro-condensed systems · CPC title
containing three or more hetero rings · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016115157A1 cover?
- The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted alip…
- Who is the assignee on this patent?
- Achillion Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Apr 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).